This evening, Hayman Capital through the entity “Coalition For Affordable Drugs” filed a petition for Inter Parties Review on a patent controlled by Shire PLC. Importantly, the patent in question supports Shire’s very profitable drug LIALDA, which according to Shire’s most recent investor presentation generated $634 million in sales in 2014, up 20% year over year.